|
|
 |
|
Viewing report
|
|
|
|
Russia Pharmaceutical Market Overview Pharma companies target Russia despite the challenges it presents
Datamonitor, Nov 2010, Pages: 187
Introduction
The Russian pharmaceutical market generated $10.1 billion in sales in 2009, growing by 14.5% between 2008 and 2009. Key growth drivers include a preference for foreign drugs rather than domestically manufactured products. The government has also designated healthcare a strategic priority for the country's future development which is expected to stimulate Russia's pharmaceutical market.
Scope
-Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property in Russia
-Assesses the size of the Russian pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
-Examines the Russian generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
-Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis
Highlights
Private health expenditure accounts for one third of all healthcare costs of which 82%% is met by out-of-pocket costs due to insufficient availability of healthcare services and medicines through the public healthcare system, as well as the widespread informal payments for healthcare services.
Registration of drugs in the Russian Federation remains a cumbersome and lengthy procedure which lacks clarity and transparency and is subject to frequent change. Cultural and language barriers present further obstacles to foreign companies 'going it alone'.
The generics industry is complex and fragmented, dominated by a small number of international generics manufacturers. Generics produced by these companies enjoy preferential uptake driven by their perceived superiority to domestically manufactured generics, with Russians choosing to pay higher prices for guaranteed quality.
Reasons to Purchase
-Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in Russia
-Quantify the size and growth of the prescription pharmaceutical market in Russia, analyzing key therapy areas, brands and companies
-Assess drivers and resistors of generic and biosimilars uptake in Russia
|
|
|
|
